No Data
Beijing Centergate Technologies (000931.SZ): The company's Pharmaceutical has been included in the 2024 National Medical Insurance Directory.
On December 11, Gelonghui announced that Beijing Centergate Technologies (000931.SZ) stated that its wholly-owned subsidiary SIHUAN PHARM holds Beijing Huasu, ShanDong Huasu, and SIHUAN PHARM controlled Duoduo Pharmaceutical have a total of 34 products included in the "Medical Insurance Catalogue 2024." This includes products such as bisoprolol fumarate tablets, benidipine hydrochloride tablets, oxycodone hydrochloride tablets, and naloxone hydrochloride injection, which were originally included in the 2023 National Medical Insurance Catalogue. The selected products remain unchanged compared to the "Medical Insurance Catalogue 2023." The future sales situation of the included products may be affected by multiple factors such as changes in the market environment and will not impact the current operation of the company.
Beijing Centergate Technologies (000931.SZ): Vice President Wang Bo resigned due to job changes.
On December 4th, Gelonghui reported that Beijing Centergate Technologies (000931.SZ) announced that the company's board of directors recently received a written resignation letter submitted by Mr. Wang Bo, the vice president of the company. Mr. Wang applied to resign from his position as vice president due to job changes, and after his resignation, he will no longer hold any position in the company. As of the date of this announcement, Mr. Wang does not hold any shares in the company and there are no commitments that he should have fulfilled but has not.
Beijing Centergate Technologies (000931.SZ): Subsidiary company Duoduo Pharmaceutical received the "Acceptance Notice" for Nifurtimox tablets from the National Medical Products Administration.
November 12th, Beijing Centergate Technologies (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical, recently received the "Acceptance Letter" issued by the National Medical Products Administration, accepting the registration application for Febuxostat tablets (specifications: 20mg, 40mg). Duoduo Pharmaceutical's Febuxostat tablets (specifications: 20mg, 40mg) were launched for research in 2022, and the indication for this application is for the long-term treatment of hyperuricemia in gout patients, not recommended for hyperuricemia without clinical symptoms.
Zhongguancun: Report for the third quarter of 2024
Beijing Centergate Technologies (000931.SZ) released its performance for the first three quarters, with net income of 51.629 million yuan, a year-on-year increase of 24.78%.
Beijing Centergate Technologies (000931.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue of 1...
beijing centergate technologies (000931.SZ) net income for the first three quarters was 51.629 million yuan, a year-on-year increase of 24.78%.
Gelonghui on October 30th, Beijing Centergate Technologies (000931.SZ) released the third quarter report, the company achieved revenue of 1.93 billion yuan in the first three quarters, a year-on-year increase of 14.96%; net income was 51.629 million yuan, a year-on-year increase of 24.78%. In the third quarter alone, revenue reached 0.656 billion yuan, an increase of 22.41% year-on-year; net income was 15.2391 million yuan.
